Search Results - "Nakamura, Motonobu"

Author Index: International Journal of Urology 2007.

Source: International Journal of Urology. Dec2007, Vol. 14 Issue 12, p1127-1136. 10p.

Author Index.

Source: Quality of Life Research. Nov2004, Vol. 13 Issue 9, p1605-1619. 15p.

Subjects: Authors, Quality of life

Perioperative Chemotherapy in Bladder and Upper Tract Urothelial Carcinoma: Outcomes by Nodal Status and Lymphovascular Invasion.

Authors: Furubayashi, Nobuki Tsujita, Jiro Takayama, Azusa et al.

Source: Cancers. Dec2025, Vol. 17 Issue 24, p3986. 14p.

Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma with Low Tumor Burden.

Authors: Furubayashi, Nobuki Tsujita, Jiro Takayama, Azusa et al.

Source: Cancers. Aug2025, Vol. 17 Issue 15, p2447. 10p.

A Case of Cystic Retroperitoneal Dedifferentiated Liposarcoma Diagnosed by Percutaneous Image-Guided Biopsy.

Authors: Morihara, Kaede Negishi, Takahito Furubayashi, Nobuki et al.

Source: Case Reports in Oncology. 2023, Vol. 16 Issue 1, p1460-1465. 6p.

J‐AVENUE: A retrospective, real‐world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first‐line maintenance therapy in Japan.

Authors: Kikuchi, Eiji Hayakawa, Nozomi Nakayama, Masashi et al.

Source: International Journal of Urology. Aug2024, Vol. 31 Issue 8, p859-867. 9p.

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis.

Authors: Matsubara, Nobuaki Miyake, Hideaki Uemura, Hiroji et al.

Source: Cancer Medicine. Jan2025, Vol. 14 Issue 1, p1-15. 15p.

Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.

Authors: Minato, Akinori Furubayashi, Nobuki Nagata, Yujiro et al.

Source: Current Oncology. Feb2024, Vol. 31 Issue 2, p862-871. 10p.

Darolutamide in Japanese patients with metastatic hormone‐sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.

Authors: Uemura, Motohide Kikukawa, Hiroaki Hashimoto, Yasuhiro et al.

Source: Cancer Medicine. Nov2024, Vol. 13 Issue 21, p1-15. 15p.

The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.

Authors: Furubayashi, Nobuki Minato, Akinori Negishi, Takahito et al.

Source: OncoTargets & Therapy. Nov2022, Vol. 15, p1321-1330. 10p.

Bone‐modifying agents are protective for symptomatic skeletal events in Radium‐223 treatment.

Authors: Blas, Leandro Shiota, Masaki Matsumoto, Takashi et al.

Source: International Journal of Urology. Nov2023, Vol. 30 Issue 11, p1029-1034. 6p.

Effects of Nitric Oxide on Renal Proximal Tubular Na⁺ Transport.

Authors: Satoh, Nobuhiko Nakamura, Motonobu Suzuki, Atsushi et al.

Source: BioMed Research International. 10/17/2017, Vol. 2017, p1-9. 9p.

Effectiveness and safety of radium‐223 dichloride in patients with castration‐resistant prostate cancer and bone metastases in real‐world practice: A multi‐institutional study.

Authors: Matsumoto, Takashi Hori, Yoshifumi Shiota, Masaki et al.

Source: International Journal of Urology. Feb2023, Vol. 30 Issue 2, p139-146. 8p.

Acneiform eruption during peficitinib treatment.

Authors: Hara, Reiko Sawada, Yu Nakamura, Motonobu

Source: Journal of Cutaneous Immunology & Allergy. Aug2022, Vol. 5 Issue 4, p139-140. 2p.

Change of genitourinary cancer patients' perception and expectations over the course of pharmacotherapy.

Authors: Satou, Yoshiaki Ieiri, Kousuke Negishi, Takahito et al.

Source: PLoS ONE. 11/22/2022, Vol. 17 Issue 11, p1-8. 8p.

A subcutaneous abscess following anti‐programmed cell death 1/programmed death‐ligand 1 antibody treatment for lung cancer.

Authors: Sugino, Hitomi Sawada, Yu Nakamura, Motonobu

Source: Journal of Cutaneous Immunology & Allergy. Jun2022, Vol. 5 Issue 3, p104-105. 2p.

Sarilumab‐induced cutaneous adverse event.

Authors: Sato, Sayaka Sawada, Yu Nakamura, Motonobu

Source: Journal of Cutaneous Immunology & Allergy. Apr2022, Vol. 5 Issue 2, p67-68. 2p.

Macular‐type cutaneous adverse reaction due to atezolizumab and pembrolizumab.

Authors: Sugino, Hitomi Sawada, Yu Nakamura, Motonobu

Source: Journal of Cutaneous Immunology & Allergy. Apr2022, Vol. 5 Issue 2, p63-64. 2p.

Selective Insulin Resistance in the Kidney.

Authors: Horita, Shoko Nakamura, Motonobu Suzuki, Masashi et al.

Source: BioMed Research International. 5/9/2016, Vol. 2016, p1-8. 8p.

Roles of Akt and SGK1 in the Regulation of Renal Tubular Transport.

Authors: Satoh, Nobuhiko Nakamura, Motonobu Suzuki, Masashi et al.

Source: BioMed Research International. 9/28/2015, Vol. 2015, p1-8. 8p.